Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Patrick Boland, MD, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.
Dr. Boland on Leveraging Triplet Chemo Regimens in Non-Resectable Liver-Only mCRC
Patrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.
Dr. Boland on Determining When to Utilize Up-front Perioperative Chemotherapy in CRC
Patrick Boland, MD, discusses determining when to utilize up-front perioperative chemotherapy for patients with colorectal cancer with liver metastases.
Dr. Boland on Efforts Underway to Optimize the Utility of ctDNA in CRC
Patrick Boland, MD, discusses the utility of circulating tumor DNA in patients with metastatic colorectal cancer.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512